
Elevance Health Is Latest Insurer To Cut Profit Targets As Costs Surge
Elevance Health Thursday became the latest health insurer to lower its profit forecast for the rest of 2025 due to rising costs in its Medicaid plans and individual policies it sells under the Affordable Care Act.
Citing the 'ongoing and industry-wide impact of elevated cost trends in ACA and Medicaid,' Elevance Health said it now expects adjusted net income per diluted share to be approximately $30.00. That compares to an earlier forecast of 2025 adjusted diluted earnings per share of $34.15 to $34.85.
'We are updating our outlook to reflect elevated medical cost trends in ACA and slower rate alignment in Medicaid,' Elevance Health president and chief executive Gail K. Boudreaux said in a statement accompanying earnings. 'While the external environment continues to evolve, we are focused on the areas within our control - managing healthcare costs, deploying targeted investments in advanced technology and value-based care delivery, and reinforcing the operational foundation that supports long-term value creation. With the embedded earnings power of our diversified Health Benefits and Carelon businesses, we remain confident in achieving at least 12% average annual growth in adjusted diluted EPS over time."
The Elevance Health report comes after government-subsidized health insurance provider Centene withdrew its 2025 financial guidance earlier this month due to higher costs in the individual health plans it sells under the Affordable Care Act as well as rising expenses from enrollees in its Medicaid plans.
Centene's announcement was only the latest from a parade of health insurance companies that have struggled in the last two years to control costs of subscribers in plans subsidized by the government. Just last week, Molina Healthcare lowered its earnings guidance for the rest of the year in the face of cost pressures in all three of the government-subsidized health insurance programs it helps manage: Medicaid, Medicare Advantage and individual coverage under the ACA, also known as Obamacare.
And in May, UnitedHealth suspended its financial outlook for the rest of the year and replaced its top executive as the parent of UnitedHealthcare grapples with rising healthcare costs in its Medicare Advantage business. Medicare Advantage plans contract with the federal government to provide health benefits to seniors.
In its second quarter, Elevance Health said net income fell 24% to $1.7 billion from $2.3 billion in the year ago quarter thanks in part to rising costs. Total revenues were up 14% to $49 billion.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
9 minutes ago
- Yahoo
Wendy's Lowers Fiscal 2025 Outlook Despite Second-Quarter Beat
Wendy's (WEN) lowered its full-year earnings and global systemwide sales outlook on Friday, even tho
Yahoo
9 minutes ago
- Yahoo
Gold futures in New York surge as tariff confusion sweeps precious metal market
Gold (GC=F) futures in New York hit intraday record highs on Friday amid reports that imports of Swiss gold bars would not be exempt from tariffs. The precious metal hit $4,490 per ounce on the Comex exchange after the Financial Times reported one-kilogram and 100-ounce bars of gold are indeed subject to 39% reciprocal tariffs on Switzerland recently announced by the Trump administration. "The move is significant because 1-kilo and 100-ounce gold bars form the backbone of much of the gold trading activity in the United States," Ryan McIntyre, senior managing partner at investment manager Sprott, told Yahoo Finance. McIntyre said contracts on the Comex exchange in New York are based on 100-ounce bars, noting "the introduction of tariffs will likely inject additional uncertainty into that market." The clarification from Customs and Border Patrol, also reported by Bloomberg, sent gold futures in New York skyrocketing as traders assessed the implications on transfers of the precious metals and how the futures market could be reshaped. "Likely imposing 39% tariffs on Swiss kilobars is akin to pouring sand into an otherwise well functioning engine," wrote Ross Norman, CEO of UK-based Metals Daily. Traders are still weighing whether the steep tariffs on Swiss kilo-bars reflect a real policy shift or a possible misclassification error. "On a broader scale, the gold market is highly liquid and global, meaning we would expect gold flows to adjust in ways that minimize disruptions," McIntyre said. Gold inventories in New York skyrocketed earlier this year as institutional investors shipped elevated amounts of physical bars to vaults in Manhattan ahead of tariff announcements. In late March inventories reached their highest level since the pandemic in 2021, according to Bloomberg data. Ines Ferre is a senior business reporter for Yahoo Finance. Follow her on X at @ines_ferre. Click here for in-depth analysis of the latest stock market news and events moving stock prices Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
9 minutes ago
- Yahoo
The Street Loves This ‘Strong Buy' Pharma Stock
Indivior (INDV) is up 90% since April and has consistently hit new highs, driven by optimism for Sublocade. INDV stock set its latest 52-week high in morning trading on Aug. 8. Technical indicators are overwhelmingly bullish. Indivior has a 100% 'Buy' rating from Barchart. Despite the current momentum, INDV is volatile and speculative. I recommend strict risk management and stop-loss strategies for any potential investment. Today's Featured Stock Valued at $3.03 billion, Indivior (INDV) is a specialty pharmaceutical company. It is engaged in discovering and developing medications and treatment for alcohol addiction, opioid overdose, cocaine intoxication, and co-occurring conditions, such as schizophrenia. Its future seems to be based on analysts' love of Sublocade, which is an extended-release injection of buprenorphine used for the treatment of moderate to severe opioid use disorder. Sublocade works by steadily releasing buprenorphine into the bloodstream, helping to reduce cravings and withdrawal symptoms associated with opioid dependence. More News from Barchart Robinhood Stock Seemingly Can't Be Stopped in 2025. Is It Too Late to Buy HOOD Here? Dear Ford Stock Fans, Mark Your Calendar for August 11 Cathie Wood Is Buying Shares of This Little-Known Ethereum Treasury Company. Should You? Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today! What I'm Watching I found today's Chart of the Day by using Barchart's powerful screening functions to sort for stocks with the highest technical buy signals; superior current momentum in both strength and direction; and a Trend Seeker 'buy' signal. I then used Barchart's Flipcharts feature to review the charts for consistent price appreciation. INDV checks those boxes. Since the Trend Seeker signaled a buy on April 25, the stock has gained 92.7%. INDV Price. vs Daily Moving Averages: Barchart Technical Indicators for Indivior Editor's Note: The technical indicators below are updated live during the session every 20 minutes and can therefore change each day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the website when you read this report. These technical indicators form the Barchart Opinion on a particular stock. Indivior shares hit a new 52-week high on Aug. 8, touching $22.36 in morning trading. Indivior has a Weighted Alpha of +128.91. INDV has an 100% 'Buy' opinion from Barchart. The stock has gained 69.29% over the past year. INDV has its Trend Seeker 'Buy' signal intact. Indivior is trading above its 20-, 50-, and 100-day moving averages. The stock made 20 new highs and gained 46.08% in the last month. Relative Strength Index (RSI) is at 90%. There's a technical support level around $21.72. Don't Forget the Fundamentals $3.03 billion market capitalization. 12.36x trailing price-earnings ratio. Revenue is projected to decline 9.09% this year and another 1.16% next year. Earnings are estimated to increase only 1.10% this year and an additional 11.48% next year. Analyst and Investor Sentiment on Indivior I don't buy stocks because everyone else is buying, but I do realize that if major firms and investors are dumping a stock, it's hard to make money swimming against the tide. It looks like Wall Street analysts are bullish on INDV, and so is Morningstar. The Wall Street analysts tracked by Barchart have issued 7 'Strong Buy' and 1 'Moderate Buy' opinion on the stock. Their price targets are between $20-$30 with a consensus of $25.83. Morningstar thinks the stock is undervalued by 23% with a fair value of $28.77. Only 958 investors monitor the stock on Seeking Alpha, which rates the stock a 'Hold.' The Bottom Line on Indivior INDV currently has momentum and is hitting new highs. Analysts seem to think a turnaround may be in its future. I caution that INDV is volatile and even speculative in the current environment, which means investors should use strict risk management and stop-loss strategies. Today's Chart of the Day was written by Jim Van Meerten. Read previous editions of the daily newsletter here. Additional disclosure: The Barchart of the Day highlights stocks that are experiencing exceptional current price appreciation. They are not intended to be buy recommendations as these stocks are extremely volatile and speculative. Should you decide to add one of these stocks to your investment portfolio it is highly suggested you follow a predetermined diversification and moving stop loss discipline that is consistent with your personal investment risk tolerance. On the date of publication, Jim Van Meerten did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data